检索历史 清除

目的:观察卡瑞利珠单抗联合白蛋白紫杉醇＋顺铂(AP)方案治疗晚期非小细胞肺癌的临床效果。方法:队列研究。抽取2018年2月至2023年2月河南省第二人民医院收治的晚期非小细胞肺癌患者60例，按随机数字表法分为化疗组和联合组，每组30例。化疗组采取AP方案治疗，联合组在化疗组的基础上采取卡瑞利珠单抗治疗。对比两组治疗效果、肿瘤标志物[糖类抗原125(CA125)、癌胚抗原(CEA)]水平、免疫功能[T淋巴细胞亚群(CD3 ＋、CD4 ＋、CD8 ＋)]及不良反应发生率。 结果:联合组疾病缓解率(60.00%，18/30)高于化疗组(33.33%，10/30)， P<0.05。治疗后，联合组CA125、CEA水平低于化疗组( P<0.05)；治疗后，联合组CD3 ＋、CD4 ＋占比高于化疗组，且CD8 ＋占比低于化疗组( P<0.05)。联合组不良反应发生率(26.67%，8/30)与化疗组(16.67%，5/30)比较差异未见统计学意义( P>0.05)。 结论:卡瑞利珠单抗联合AP方案应用于晚期非小细胞肺癌患者中疗效显著，可降低肿瘤标志物水平，提高机体免疫功能，且联合方案具有较高安全性，不会增加不良反应发生率。

Objective:To observe the clinical effect of camrelizumab combined with albumin paclitaxel+ cisplatin (AP) in the treatment of advanced non-small cell lung cancer.Methods:Sixty patients with advanced non-small cell lung cancer treated in the Second People’s Hospital of Henan Province from February 2018 to February 2023 were selected for the cohort study, and they were divided into a chemotherapy group and a combination group according to random number table method, with 30 cases in each group. The chemotherapy group was treated with AP regimen, and the combination group was treated with camrelizumab based on the treatment of the chemotherapy group. The curative effect, levels of tumor markers, including carbohydrate antigen 125 (CA125) and carcinoembryonic antigen (CEA), immune function assessed by T lymphocyte subsets, including cluster of differentiation 3 + (CD3 + ), cluster of differentiation 4 + (CD4 + ) and cluster of differentiation 8 + (CD8 + ), and incidence of adverse reactions of the two groups were compared. Results:The disease remission rate in the combination group (60.00%, 18/30) was higher than that in the chemotherapy group (33.33%, 10/30), P<0.05. After treatment, the levels of CA125 and CEA in the combination group were lower than those in the chemotherapy group ( P<0.05). Compared with the chemotherapy group, the proportions of CD3 + and CD4 + in the combination group were higher, and the proportion of CD8 + was lower after treatment ( P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the combination group (26.67%, 8/30) and the chemotherapy group (16.67%, 5/30), P>0.05. Conclusions:Camrelizumab combined with AP regimen is effective in the treatment of advanced non-small cell lung cancer; it can reduce the levels of tumor markers, improve immune function, and provide a high safety, without increasing the incidence of adverse reactions.